GSK to Buy BMS’s HIV Portfolio

27285-hi-logo_gskDrug giant GlaxoSmithKline has reached a deal to acquire Bristol-Myers Squibb’s HIV portfolio.

GSK will pay $350 million up front and could pay an additional $1 billion depending on developmental and sales milestones.

GSK did the deal through its subsidiary ViiV Healthcare, a HIV specialty company established by GlaxoSmithKline and Pfizer in 2009.

It is actually two separate deals — one to buy BMS’s late-stage HIV assets and another to buy assets earlier in the developmental pipeline. The deals should close independently during the first half of 2016.


This entry was posted in Pharmaceuticals, Uncategorized and tagged , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s